Skip to content

GLP-1 nausea: how common it is, how long it lasts, what helps

Updated Sep 30, 2026. Numbers in brackets link to the source each fact comes from.

Nausea is the side effect people report most often on GLP-1 medicines, and the FDA labels show it is most common while the dose is still being raised. MedlinePlus, the National Library of Medicine’s health site, lists glutides, the drug class that includes semaglutide, among the medicines that can cause nausea and vomiting [1]. For most people in the trials it eased with time, but a few signs mean you should call your prescriber rather than wait.

How often it happened in the trials

Each label reports how many trial participants had nausea on the drug and how many had it on placebo, a dummy shot or pill. The placebo column matters: in every trial some people felt sick without the medicine. Nausea is the first row of the side-effect table on each of these labels.

Medicine and trial group Placebo On the medicine
Zepbound 5, 10 and 15 mg, weight trials 8% 25%, 29%, 28% [2]
Wegovy injection 2.4 mg, weight trials 16% 44% [3]
Wegovy injection 7.2 mg trial (2.4 mg arm in brackets) 13% 39% (35%) [4]
Foundayo 5.5, 9 and 17.2 mg, weight trials 10% 26%, 34%, 35% [6]
Ozempic 0.5 and 1 mg, diabetes trials 6.1% 15.8%, 20.3% [7]
Mounjaro 5, 10 and 15 mg, diabetes trials 4% 12%, 15%, 18% [8]

The Wegovy label has no separate table for the tablets. It says the side effects in the 25 mg tablet trial were similar in type and frequency to the injection table above [5].

These rows come from different trials with different people, so they do not rank one drug against another. The Ozempic and Mounjaro figures come from people with type 2 diabetes, not from weight-loss trials. For every rate on each label, see the pages for Zepbound, Wegovy, Foundayo, Ozempic and Mounjaro.

How long it lasts

The labels describe timing in general terms, not a number of days. On Zepbound, most nausea, vomiting and diarrhea happened while the dose was being raised and became less common later [9]. The Mounjaro label says the same [11]. On Foundayo, these symptoms were more common during the dose-raising period and then fell [10]. The Ozempic label says most reports came during dose escalation [12].

Stopping because of side effects was uncommon but real. In the Zepbound weight trials, 4.8%, 6.3% and 6.7% of people on the three doses stopped for good because of side effects, against 3.4% on placebo, and most of those who stopped did so in the first few months because of stomach and gut problems [13].

What the labels tell prescribers

  • Raise the dose in steps: the Wegovy label ties its step-by-step schedule to lowering the risk of gut side effects [14].
  • If a step is hard to tolerate, the Wegovy label says to consider waiting 4 weeks before the next increase [15].
  • The Zepbound label says a lower maintenance dose can be considered if the chosen one is not tolerated [16].

These are the prescriber’s decisions. If nausea is making it hard to eat or drink, tell the person who prescribed the medicine before your next dose rather than skipping or changing doses on your own.

Self-care tips from MedlinePlus

This is MedlinePlus’s general advice for nausea from any cause, not advice written for GLP-1 medicines.

  • Eat 6 to 8 small meals a day instead of 3 large ones [17].
  • Choose bland foods such as crackers, toast, rice, potatoes, noodles, or baked chicken or fish [18].
  • Aim for 8 to 10 cups of clear liquids a day so you do not dry out [19].
  • Stay away from foods with strong smells, and from caffeine, alcohol and fizzy drinks [20].
  • Sit up after you eat instead of lying down [21].

Advice written for GLP-1 treatment says much the same. A 2025 joint advisory from four obesity and nutrition groups (the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society) says nausea often comes in the morning or after long stretches without eating. It suggests smaller, more frequent meals and avoiding fatty or high-fiber foods in the first few days of treatment [27].

When to call a doctor

MedlinePlus says to contact your provider if you cannot keep food or liquid down, vomit three or more times in a day, or have nausea for more than 48 hours [22].

The medication guides add warnings that apply to these drugs specifically:

  • Dehydration and the kidneys. Nausea, vomiting and diarrhea can dry you out, which can lead to kidney problems; drink fluids and tell your provider right away if the symptoms do not go away [23].
  • Pancreatitis. Stop the medicine and call right away if you have severe stomach pain that will not go away, with or without nausea or vomiting; the pain may reach your back [24].
  • Gallbladder problems. Call if you have pain in your upper stomach, yellow skin or eyes, fever, or clay-colored stools [25].
  • Severe stomach problems. In the Wegovy weight trials, severe gut side effects were reported by 4.1% of people on the injection and 0.9% on placebo [26].

Sources

  1. Medicines or medical treatments, such as glutides (a type of medicine used to treat diabetes or obesity), cancer chemotherapy , or radiation treatment medlineplus.gov, read Sep 27, 2026.
  2. Adverse Reaction Placebo (N=958) % ZEPBOUND 5 mg (N=630) % ZEPBOUND 10 mg (N=948) % ZEPBOUND 15 mg (N=941) % Nausea 8 25 29 28 dailymed.nlm.nih.gov, read Sep 27, 2026.
  3. Placebo N=1,261 % WEGOVY Injection (2.4 mg Once Weekly) N=2,116 % Nausea 16 44 dailymed.nlm.nih.gov, read Sep 27, 2026.
  4. Placebo N=303 % WEGOVY Injection (2.4 mg Once Weekly) N=304 % WEGOVY Injection (7.2 mg Once Weekly) N=1,311 % Nausea 13 35 39 dailymed.nlm.nih.gov, read Sep 27, 2026.
  5. In the clinical trial with WEGOVY 25 mg tablets, the types and frequency of common adverse reactions were similar to those listed in Table 3. dailymed.nlm.nih.gov, read Sep 27, 2026.
  6. Adverse Reaction Placebo (N=1,576) % FOUNDAYO 5.5 mg once daily (N=1,051) % FOUNDAYO 9 mg once daily (N=1,055) % FOUNDAYO 17.2 mg once daily (N=1,049) % Nausea 10 26 34 35 dailymed.nlm.nih.gov, read Sep 27, 2026.
  7. Adverse Reaction Placebo (N=262) % OZEMPIC 0.5 mg (N=260) % OZEMPIC 1 mg (N=261) % Nausea 6.1 15.8 20.3 dailymed.nlm.nih.gov, read Sep 27, 2026.
  8. Adverse Reaction Placebo (N=235) % MOUNJARO 5 mg (N=237) % MOUNJARO 10 mg (N=240) % MOUNJARO 15 mg (N=241) % Nausea 4 12 15 18 dailymed.nlm.nih.gov, read Sep 27, 2026.
  9. The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time. dailymed.nlm.nih.gov, read Sep 27, 2026.
  10. The incidence of nausea, vomiting, and diarrhea was higher during the FOUNDAYO dosage escalation period and decreased over time. dailymed.nlm.nih.gov, read Sep 27, 2026.
  11. The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time. dailymed.nlm.nih.gov, read Sep 27, 2026.
  12. The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. dailymed.nlm.nih.gov, read Sep 27, 2026.
  13. Across both trials, 4.8%, 6.3%, and 6.7% of patients treated with 5 mg, 10 mg, and 15 mg of ZEPBOUND, respectively, permanently discontinued treatment as a result of adverse reactions compared to 3.4% of patients treated with placebo. The majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions. dailymed.nlm.nih.gov, read Sep 27, 2026.
  14. Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions dailymed.nlm.nih.gov, read Sep 27, 2026.
  15. If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks. dailymed.nlm.nih.gov, read Sep 27, 2026.
  16. Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage. dailymed.nlm.nih.gov, read Sep 27, 2026.
  17. Try to eat 6 to 8 small meals throughout the day, instead of 3 big meals: medlineplus.gov, read Sep 27, 2026.
  18. Eat bland foods. Examples are crackers, English muffins, toast, baked chicken and fish, potatoes, noodles, and rice. medlineplus.gov, read Sep 27, 2026.
  19. To make sure your body has enough fluids try to drink 8 to 10 cups (2 to 2.5 liters) of clear liquids every day. medlineplus.gov, read Sep 27, 2026.
  20. Avoid foods with strong smells. Avoid caffeine, alcohol, and carbonated drinks. medlineplus.gov, read Sep 27, 2026.
  21. Sit up after you eat. Do not lie down. medlineplus.gov, read Sep 27, 2026.
  22. Cannot keep any food or liquid down Vomit three or more times in one day Have nausea for more than 48 hours medlineplus.gov, read Sep 27, 2026.
  23. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away. dailymed.nlm.nih.gov, read Sep 27, 2026.
  24. Stop using WEGOVY and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back. dailymed.nlm.nih.gov, read Sep 27, 2026.
  25. Gallbladder problems have happened in some people who use ZEPBOUND. Tell your healthcare provider right away if you get symptoms of gallbladder problems which may include: pain in your upper stomach (abdomen) fever yellowing of skin or eyes (jaundice) clay-colored stools dailymed.nlm.nih.gov, read Sep 27, 2026.
  26. Severe gastrointestinal adverse reactions were reported in 4.1% and 0.9% of WEGOVY injection and placebo-treated patients, respectively dailymed.nlm.nih.gov, read Sep 27, 2026.
  27. Nausea is the most common GI side effect and often occurs in the morning or after longer periods without eating. Smaller, more frequent meals and avoiding fatty or high fiber foods during the first few days of treatment can help alleviate symptoms pmc.ncbi.nlm.nih.gov, read Sep 28, 2026.

This page reports what official sources say; it is not medical advice. Medical disclaimer.